Physician profile
John R Smart
NPI 1861574451
$3,855.72
in general payments reported to CMS, 2019-2025
31 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $500 · 2021: $656 · 2022: $699 · 2023: $541 · 2024: $578 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,626.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $570.81 | 2022-2025 | |
| Amgen INC. | $449.01 | 2020-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $439.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $326.46 | 2019-2025 | Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $277.20 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
| Glaxosmithkline, LLC. | $262.35 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $180.11 | 2021-2024 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.68 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $177.48 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $145.51 | 2019-2023 | Xarelto |
| Allergan, INC. | $118.04 | 2019-2020 | |
| Lilly USA, LLC | $93.38 | 2019-2025 | Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $86.68 | 2020-2021 | |
| Mannkind Corporation | $72.73 | 2025 | |
| Esperion Therapeutics, INC. | $63.58 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.74 | 2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $36.39 | 2019 | |
| Xeris Pharmaceuticals, INC. | $36.05 | 2022-2023 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $33.89 | 2025 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.23 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $30.37 | 2023-2024 | Gemtesa |
| Mylan Specialty L.P. | $30.29 | 2023-2024 | Yupelri |
| Astellas Pharma US INC | $27.56 | 2021-2023 | Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $24.24 | 2019-2023 | Eliquis |
| Abbott Laboratories | $23.17 | 2022 | |
| Pfizer INC. | $21.27 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $15.54 | 2025 | Rexulti |
| Lundbeck LLC | $15.31 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $13.31 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.41 | 2019 | |
| Amarin Pharma, INC. | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Smart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.